Search for:
Close
News
Press releases
Newsletter
Media Archive
Subscribe
Series of digital events
Commercial collaborations
Drug Development
Cancer
Infections
Tuberculosis
Our Pipeline
Publications
Contact us
Hamlet Biopharma
Patents
Board & Executive Team
Finance and Investor Relations
Financial Reports
Financial Calendar
General Meetings
The share
Spotlight Stock Market
Prospectus 2024
Merger Hamlet-SelectImmune
Close
News
Press releases
Newsletter
Media Archive
Subscribe
Series of digital events
Commercial collaborations
Drug Development
Cancer
Infections
Tuberculosis
Our Pipeline
Publications
Contact us
Hamlet Biopharma
Patents
Board & Executive Team
Finance and Investor Relations
Financial Reports
Financial Calendar
General Meetings
The share
Spotlight Stock Market
Prospectus 2024
Search for:
Pipeline
15 projects, all with proven therapeutic efficacy in animal models
Cutting- edge biotech pipeline: targeting cancer, infections and inflammation
An innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections.
Hamlet BioPharma AB
Klinikgatan 32
SE-222 42 Lund
info@hamletbiopharma.com
Org. no. 556568-8958
Subscribe to receive newsletters
© 2025
Hamlet BioPharma.
